Acura Says Results from Top-Line Study Assessing Abuse Liability 'Not Statistically Significant'

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR ) today announced top-line results from Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug abusers assessing the abuse liability of snorting a crushed hydrocodone bitartrate with acetaminophen tablet formulated with Acura's abuse deterrent AVERSION technology (AVERSION H&A). The results for AVERSION H&A in Study